Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2015

01-10-2015 | Research Article

Suboptimal antimicrobial drug exposure in patients with renal impairment

Authors: David Czock, Martino Spitaletta, Frieder Keller

Published in: International Journal of Clinical Pharmacy | Issue 5/2015

Login to get access

Abstract

Background Recommendations on drug dose adjustment in patients with renal impairment may vary between the references. It is often unknown which approach the dosing schemes were based on and what drug exposure is likely to be achieved. Objective To develop a simple method to evaluate recommended dosing schemes for patients with renal impairment, to apply this method to selected antibacterial drugs in order to evaluate expected drug concentrations using dosing schemes recommended for patients with severe infections, and to evaluate the expected consequences. Setting This was a theoretical study, which was based on data from published clinical trials. Methods Clinically established dosing schemes for 46 antibacterial drugs, as recommended for patients with renal impairment in the Summary of Product Characteristics, were analysed using a newly developed graphical method. Consistency of the dosing schemes with two general dose adjustment rules, the proportional rule and the eliminated fraction rule, was determined and drug exposure was predicted. Main outcome measure Predicted drug exposure. Consistency of recommended dosing schemes with the general dose adjustment rules. Results Only 30 % of the recommended dosing schemes were associated with similar average concentrations as expected in patients with normal renal function (44 % were associated with higher and 26 % with lower concentrations). The highest median exposure was found in beta-lactams (170 %, range 58–443 %, for creatinine clearance of <15 ml/min, and 155 %, range 54–232 %, for creatinine clearance of 15 to <30 ml/min), where the medians were significantly different from 100 % (P < 0.02). Consistency with a dosing rule was found in 59 % of the dosing schemes (proportional rule 46 %, eliminated fraction rule 50 %, both rules 4 %). Conclusions Relative low exposure was found for several drugs, including ceftazidime, cefotaxime, imipenem, erythromycin, ciprofloxacin, levofloxacin, and teicoplanin, where dosing schemes should be reconsidered or used only in clinical situations where a lower than maximum exposure appears adequate. General application of the proportional rule for calculating drug dose adjustments would lead to lower than clinically established dose practice for 44 % of drugs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122–37.CrossRefPubMed Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122–37.CrossRefPubMed
3.
go back to reference Dettli L. The kidney in pre-clinical and clinical pharmacokinetics. Jpn J Clin Pharmacol. 1984;15:241–54.CrossRef Dettli L. The kidney in pre-clinical and clinical pharmacokinetics. Jpn J Clin Pharmacol. 1984;15:241–54.CrossRef
4.
go back to reference Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107:647–55.PubMedCentralPubMed Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107:647–55.PubMedCentralPubMed
5.
go back to reference Kunin CM. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Ann Intern Med 1967;67:151–8. Kunin CM. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. Ann Intern Med 1967;67:151–8.
6.
go back to reference Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ. 2005;331:263.PubMedCentralCrossRefPubMed Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ. 2005;331:263.PubMedCentralCrossRefPubMed
7.
go back to reference World Health Organization. The selection and use of essential medicines. World Health Organ Tech Rep Ser 2011; 965:i–xiv,1–249. World Health Organization. The selection and use of essential medicines. World Health Organ Tech Rep Ser 2011; 965:i–xiv,1–249.
8.
go back to reference Czock D, Keller F, Paar WD, Thalhammer F. Renal replacement therapy in critically ill patients: how to dose antibiotics during continuous hemofiltration. Intensiv- und Notfallbehandlung. 2008;33:169–83.CrossRef Czock D, Keller F, Paar WD, Thalhammer F. Renal replacement therapy in critically ill patients: how to dose antibiotics during continuous hemofiltration. Intensiv- und Notfallbehandlung. 2008;33:169–83.CrossRef
9.
go back to reference Czock D, Keller F. Dosing adjustment according to Dettli’s rule: measured pharmacokinetics in kidney patients versus urinary recovery in healthy individuals [abstract]. Br J Clin Pharmacol. 2009;68(Suppl 1):22. Czock D, Keller F. Dosing adjustment according to Dettli’s rule: measured pharmacokinetics in kidney patients versus urinary recovery in healthy individuals [abstract]. Br J Clin Pharmacol. 2009;68(Suppl 1):22.
10.
go back to reference Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385–405.CrossRefPubMed Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385–405.CrossRefPubMed
11.
go back to reference van Dalen R, Vree TB, Baars AM, Termond E. Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol. 1986;30:597–605.CrossRefPubMed van Dalen R, Vree TB, Baars AM, Termond E. Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol. 1986;30:597–605.CrossRefPubMed
12.
go back to reference Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug prescribing in renal failure. Philadelphia: American College of Physicians; 2007. Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug prescribing in renal failure. Philadelphia: American College of Physicians; 2007.
13.
go back to reference Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol. 1984;18:183–93.PubMedCentralCrossRefPubMed Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol. 1984;18:183–93.PubMedCentralCrossRefPubMed
14.
go back to reference Campise M. Neurological complication during imipenem/cilastatin therapy in uraemic patients. Nephrol Dial Transplant. 1998;13:1895–6.CrossRefPubMed Campise M. Neurological complication during imipenem/cilastatin therapy in uraemic patients. Nephrol Dial Transplant. 1998;13:1895–6.CrossRefPubMed
15.
go back to reference Sacristán JA, Soto JA, de Cos MA. Erythromycin-induced hypoacusis: 11 new cases and literature review. Ann Pharmacother. 1993;27:950–5.PubMed Sacristán JA, Soto JA, de Cos MA. Erythromycin-induced hypoacusis: 11 new cases and literature review. Ann Pharmacother. 1993;27:950–5.PubMed
16.
go back to reference MacGowan AP, White LO, Brown NM, Lovering AM, McMullin CM, Reeves DS. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function. J Antimicrob Chemother. 1994;33:1051–4.CrossRefPubMed MacGowan AP, White LO, Brown NM, Lovering AM, McMullin CM, Reeves DS. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function. J Antimicrob Chemother. 1994;33:1051–4.CrossRefPubMed
17.
go back to reference Jones EM, McMullin CM, Hedges AJ, Lovering AM, White LO, Reeves DS, et al. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother. 1997;40:121–4.CrossRefPubMed Jones EM, McMullin CM, Hedges AJ, Lovering AM, White LO, Reeves DS, et al. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother. 1997;40:121–4.CrossRefPubMed
18.
go back to reference Pea F, Poz D, Viale P, Pavan F, Furlanut M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother. 2006;58:380–6.CrossRefPubMed Pea F, Poz D, Viale P, Pavan F, Furlanut M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother. 2006;58:380–6.CrossRefPubMed
19.
go back to reference Derbyshire N, Webb DB, Roberts D, Glew D, Williams JD. Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function. J Antimicrob Chemother. 1989;23:869–76.CrossRefPubMed Derbyshire N, Webb DB, Roberts D, Glew D, Williams JD. Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function. J Antimicrob Chemother. 1989;23:869–76.CrossRefPubMed
20.
go back to reference Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, et al. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol. 2005;60:807–11.CrossRefPubMed Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, et al. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol. 2005;60:807–11.CrossRefPubMed
21.
go back to reference Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37:632–8.CrossRefPubMed Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37:632–8.CrossRefPubMed
22.
go back to reference Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother. 2010;54:460–5.PubMedCentralCrossRefPubMed Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother. 2010;54:460–5.PubMedCentralCrossRefPubMed
23.
go back to reference Eyler RF, Mueller BA. Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv Chronic Kidney Dis. 2010;17:392–403.CrossRefPubMed Eyler RF, Mueller BA. Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv Chronic Kidney Dis. 2010;17:392–403.CrossRefPubMed
24.
go back to reference Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol. 2009;5:475–87.CrossRefPubMed Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol. 2009;5:475–87.CrossRefPubMed
25.
go back to reference Keller F, Borner K, Schwarz A, Offermann G, Lode H. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit. 1987;9:148–53.CrossRefPubMed Keller F, Borner K, Schwarz A, Offermann G, Lode H. Therapeutic aminoglycoside monitoring in renal failure patients. Ther Drug Monit. 1987;9:148–53.CrossRefPubMed
26.
go back to reference Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2011;7:226–35.CrossRefPubMed Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2011;7:226–35.CrossRefPubMed
27.
go back to reference Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–34.CrossRefPubMed Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–34.CrossRefPubMed
Metadata
Title
Suboptimal antimicrobial drug exposure in patients with renal impairment
Authors
David Czock
Martino Spitaletta
Frieder Keller
Publication date
01-10-2015
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0141-0

Other articles of this Issue 5/2015

International Journal of Clinical Pharmacy 5/2015 Go to the issue